About US
Contact us
-
J&J CEO promises talc is asbestos-free, but spurns his chance to tell Congress whyCompanies embroiled in controversies often send top execs to face questions in Congress. That's not the case for Johnson & JohnsonCEO Alex Gorsky, who has spurned "repeated" requests froma House2019/12/11
-
Roche extends Spark deal offer for shorter period. Are antitrust decisions finally near?For the past half a year or so, Roche has repeatedly postponed its tender offer deadline for Spark Therapeutics, typically fora month each time. This time around, the extension only lasts a week. Ins2019/12/10
-
Samsung execs face jail for destroying evidence in Biogen JV fraud probeSamsung BioLogics has fought accusations that it inflated the value of its Biogen biosimilar joint venture Samsung Bioepis, breaking accounting rules in the process. Counter to that defense? The fact2019/12/10
-
ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLLORLANDO, FLORIDA—AbbVie and Roche have been fielding their fair share of questions about how well a fixed-duration regimen of Venclexta and Rituxan cankeep chronic lymphocytic leukemia (CLL) from ret2019/12/9
-
ASH: Gilead Sciences touts 'astounding' Yescarta survival results at 3 yearsORLANDO, FLORIDA—How long can a single infusion of Gilead Sciences CAR-T drug Yescarta continue helpingpatients with refractory large B-cell lymphoma? Pretty long, the companyshowed Saturday. Among p2019/12/9
-
Gilead, seeking HIV patent extension, faces 'gamesmanship' claims from patient groupGilead has faced criticism and lawsuits over its development timeline forHIV medicines, and the topic resurfaced this week as advocates challenged the company’s effort to scorepatent extensions. In a2019/12/6
-
FiercePharmaAsia—Astellas' $3B gene therapy bet; China's PD-1 coverage; Hanmi-Rapt I-O dealDue to the Thanksgiving holiday, we're bringing you two weeks of biopharma movement in this issue. Astellas is marching into gene therapy with a $3 billion buyout of Audentes Therapeutics. Only one P2019/12/6
-
Novartis' Sandoz, not 'ashamed' of generics focus, is aiming for Teva's top spot: CEOSeveral major generics players have been shifting focus onto innovative medicines, but don’t expect that from Sandoz, the Novartis subsidiary’s newly minted CEO said. In fact, it is coming after Teva2019/12/5
-
Gilead, HHS kick off program to provide PrEP drugs Truvada, Descovy for freeGilead and the U.S. Department ofHealth and Human Services(HHS) are locked in a patent dispute over HIV prevention meds, but as the fight plays out, they’re also partners in anew programto provide th2019/12/5
-
DOJ inks price fixing settlement with small generics player. Will others follow?Top generics players have faced years of price-fixing heat, and now federal prosecutors have inked another settlement with a small company. The upshot? Prosecutors have another firm cooperating in th2019/12/4